BioVie Inc. Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Forfeitures
BioVie Inc. (BIVI) reported Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Forfeitures of 2.69 thousand shares for the 12-month period ending 2025-06-30, per its 10-K filed 2026-08-13.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures · last filed 2026-08-13
- BioVie Inc. share-based compensation arrangement by share-based payment award, non-option equity instruments, forfeitures for the quarter ending 2025-06-30 was -25.82K shares.
- BioVie Inc. share-based compensation arrangement by share-based payment award, non-option equity instruments, forfeitures for the quarter ending 2025-03-31 was 25.60K shares.
- BioVie Inc. share-based compensation arrangement by share-based payment award, non-option equity instruments, forfeitures for the quarter ending 2024-12-31 was 1.75K shares.
- BioVie Inc. share-based compensation arrangement by share-based payment award, non-option equity instruments, forfeitures for the quarter ending 2024-09-30 was 1.16K shares.
- BioVie Inc. share-based compensation arrangement by share-based payment award, non-option equity instruments, forfeitures for fiscal 2025 was 2.69K shares.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Forfeitures 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Forfeitures 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Forfeitures 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Forfeitures 12 month | Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Forfeitures 12 month as first filed |
|---|---|---|---|---|---|
| 2025-06-30 | -25.82K shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-08-13 | -220.00 shares derived: sum of 2 quarters · filed 2026-08-13 | 1.53K shares derived: sum of 3 quarters · filed 2026-08-13 | 2.69K shares 10-K · filed 2026-08-13 | |
| 2025-03-31 | 25.60K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2025-05-12 | 27.35K shares derived: sum of 2 quarters · filed 2025-05-12 | 28.51K shares 10-Q · filed 2025-05-12 | 18.31K shares derived: sum of 4 quarters · filed 2026-08-06 | |
| 2024-12-31 | 1.75K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2025-02-11 | 2.91K shares 10-Q · filed 2025-02-11 | -7.29K shares derived: sum of 3 quarters · filed 2026-08-06 | -7.29K shares derived: sum of 4 quarters · filed 2026-08-06 | |
| 2024-09-30 | 1.16K shares 10-Q · filed 2024-11-13 | -9.04K shares derived: sum of 2 quarters · filed 2026-08-06 | -9.04K shares derived: sum of 3 quarters · filed 2026-08-06 | ||
| 2024-06-30 | -10.20K shares derived: S-1/A 12 month − 10-Q 9 month · filed 2026-08-06 | -10.20K shares derived: sum of 2 quarters · filed 2026-08-06 | 103.00 shares S-1/A · filed 2026-08-06 | 1.03K shares 10-K · filed 2024-09-30 | |
| 2024-03-31 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2024-05-14 | 10.30K shares 10-Q · filed 2024-05-14 | |||
| 2023-12-31 | 10.30K shares 10-Q · filed 2024-02-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aspire Biopharma Holdings, Inc. (ASBP) | United States | $0.012B | -0.60 |
| ADIAL PHARMACEUTICALS, INC. (ADIL) | United States | $0.012B | |
| Phio Pharmaceuticals Corp. (PHIO) | United States | $0.012B | -0.92 |
| Tempest Therapeutics, Inc. (TPST) | United States | $0.013B | |
| Scienture Holdings, Inc. (SCNX) | United States | $0.012B | -0.38 |
| KIORA PHARMACEUTICALS INC (KPRX) | United States | $0.012B | |
| Dare Bioscience, Inc. (DARE) | United States | $0.011B | |
| AEON Biopharma, Inc. (AEON) | United States | $0.013B | -0.36 |
| MUSTANG BIO, INC. (MBIO) | United States | $0.013B | |
| Vistagen Therapeutics, Inc. (VTGN) | United States | $0.013B | -0.14 |